NEW YORK, Aug. 12, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased CorMedix, Inc. (NYSE MKT:CRMD) securities between March 12, 2011 and June 29, 2015.
Click here to learn about the case: http://docs.wongesq.com/CRMD-Info-Request-Form-845. There is no cost or obligation to you.
The complaint alleges that, among other allegations, during the Class Period defendants' overstated the cost effectiveness and effectiveness of Neutrolin compared to currently established medical protocol, failed to disclose the use of paid stock promoters, and that insiders enriched themselves at the expense of shareholders by selling stock at inflated prices.
On June 29, 2015, an article by The Pump Stopper and featured on Seeking Alpha alleged that personnel involved in the formation of CorMedix had faced prior accusations of fraud, that Neutrolin's performance in clinical trials was vastly overstated, and that the Company had engaged stock promoters in order to inflate the Company's share price.
If you suffered a loss in CorMedix you have until September 4, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/CRMD-Info-Request-Form-845.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.